Table 2 Characteristics of the population
Variable | Overall population N = 35 |
|---|---|
Demographic data | |
- Age (years) | 48 [37–57] |
- Male sex | 31 (89) |
- BMI (kg/m2) | 25 [22–29] |
Admission | |
- Polytrauma | 30 (86) |
- Non-traumatic surgery | 5 (14) |
SAPS II | 42 [34–51] |
Presumed/confirmed site of infection | |
- Pulmonary infection | 31 (89) |
- Intra-abdominal infection | 3 (9) |
- Intravascular-catheter-related infection | 1 (3) |
Bacteremia | 2 (6) |
Use of vasopressors | 12 (34) |
Modified SOFA score* | 3 [1–6] |
CLCr the day of therapeutic drug monitoring | 166 [159–191] |
Antimicrobial therapy | |
- Duration of antibiotic therapy before TDM | 2 [1–3] |
- Association with aminoglycoside or quinolone | 8 (23) |
- De-escalation | 9 (26) |
- Total duration of antimicrobial therapy (days) | 7 [5–7] |
Type of pathogen | |
- Enterobacteriaceae | 33 (94) |
- Staphylococcus spp. | 18 (51) |
- Haemophilus influenzae | 8 (23) |
- Non-fermenting GNB | 3 (9) |
- Other | 3 (9) |
Polymicrobial infection | 20 (57) |
Non-documented infection | 1 (3) |
PK/PD targets | |
- Piperacillin unbound concentrations (mg/L) | 36.4 [27.7–44.3] |
Empirical underdosing for piperacillin | 0 (0) |
Excessive dosing for piperacillin | 0 (0) |
- Tazobactam unbound concentrations (mg/L) | 4.55 [3.57–5.88] |
Empirical underdosing for tazobactam | 1 (3) |
- PIP/TAZ ratio | 9.1 [6.9–11.1] |
Clinical outcomes | |
- Therapeutic failure before end of treatment | 2 (6) |
- Relapse after end of treatment | 1 (3) |
Secondary resistance to PTZ | 3 (9) |
MV duration (days) | 14 [4–26] |
ICU length of stay (days) | 22 [14–37] |
ICU mortality | 0 (0) |